BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36637083)

  • 1. Zerumbone combined with gefitinib alleviates lung cancer cell growth through the AKT/STAT3/SLC7A11 axis.
    Wang JG; Li DL; Fan R; Yan MJ
    Neoplasma; 2023 Feb; 70(1):58-70. PubMed ID: 36637083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
    Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kaempferol suppresses glioma progression and synergistically enhances the antitumor activity of gefitinib by inhibiting the EGFR/SRC/STAT3 signaling pathway.
    Zhou J; Liu Y; Chen J; Xiong N; Yi D
    Drug Dev Res; 2023 May; 84(3):592-610. PubMed ID: 36852868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
    Huang L; Hou M; Liu J; Li Y; Shen W; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):771-781. PubMed ID: 36419390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis.
    Yan WY; Cai J; Wang JN; Gong YS; Ding XB
    Neoplasma; 2022 May; 69(3):648-656. PubMed ID: 35330996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model.
    Shanmugam MK; Rajendran P; Li F; Kim C; Sikka S; Siveen KS; Kumar AP; Ahn KS; Sethi G
    Mol Carcinog; 2015 Oct; 54(10):971-85. PubMed ID: 24797723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zerumbone causes Bax- and Bak-mediated apoptosis in human breast cancer cells and inhibits orthotopic xenograft growth in vivo.
    Sehrawat A; Arlotti JA; Murakami A; Singh SV
    Breast Cancer Res Treat; 2012 Nov; 136(2):429-41. PubMed ID: 23053663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
    Pan Y; Li X; Duan J; Yuan L; Fan S; Fan J; Xiaokaiti Y; Yang H; Wang Y; Li X
    Mol Pharmacol; 2015; 87(3):378-90. PubMed ID: 25488183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of Fuzheng Kang'ai Recipe Combined Gefitinib on Lung Cancer A549 Cells and Its Mecha- nism Research].
    Yang XB; Chen X; Wu WY; Long SQ; Chen SM; Han SW
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Nov; 36(11):1340-1344. PubMed ID: 30641628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.
    Xu F; Tian Y; Huang Y; Zhang LL; Guo ZZ; Huang JJ; Lin TY
    Chin J Cancer; 2011 Oct; 30(10):701-11. PubMed ID: 21959047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
    Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
    Zhang K; Wang L; Wei A; Jia X; Liu X
    Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway.
    Chen SY; Zhang GC; Shu QJ
    Pharm Biol; 2021 Dec; 59(1):1294-1304. PubMed ID: 34543169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy.
    Song X; Han X; Yu F; Zhang X; Chen L; Lv C
    Theranostics; 2018; 8(8):2217-2228. PubMed ID: 29721074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
    Jin H; Jiang AY; Wang H; Cao Y; Wu Y; Jiang XF
    Mol Med Rep; 2017 Sep; 16(3):3475-3481. PubMed ID: 28713965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
    Hu Z; Zeng Q; Zhang B; Liu H; Wang W
    Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib.
    Song X; Wang X; Liu Z; Yu Z
    Front Oncol; 2020; 10():597434. PubMed ID: 33425751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.